European Pharmaceutical Review |
Spiriva Respimat (Tiotropium) Gets Asthma Indication in US
Medscape The US Food and Drug Administration (FDA) has approved the long-acting muscarinic antagonist tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for long-term maintenance treatment of asthma in people aged 12 years and older, according to a … FDA approves Boehringer's asthma treatment FDA approves asthma treatment Spiriva Respimat |
View full post on asthma – Google News